Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Applied Nanoscience Inc. (ANI) (PINKSHEETS:APNN), a nanotechnology-based filtration company, today issued a progress report to its investors relating to progress in commercializing the disposable NanoFense™ Protective Face Mask, designed to offer superior protection against a broad spectrum of harmful virus, bacteria and fungi.Amarin Corp. (NASDAQ:AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.Adolor Corporation (Nasdaq:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD).Abbott (NYSE:ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.CellCyte Genetics Corporation (OTC:CCYG) announced the appointment of Dr. Douglas Cerretti as Chief Science Officer and Director of Business Development effective November 1, 2009.DuPont (NYSE:DD) and BSES Limited announced a research, development and commercialization alliance to improve productivity and use of sugarcane varieties.Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, announced The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced the company will highlight its technology at two worldwide vaccine conferences next week. Dr. David Weiner, Chair of Inovio’s Scientific Advisory Board, and Niranjan Sardesai, Senior Vice President, SVP, Research and Development will speak on Inovio’s DNA vaccine development.Inhibitex, Inc. (Nasdaq:INHX), announced Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended September 30, 2009.Medtronic, Inc. (NYSE:MDT) announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives.Mach One Corporation (OTC:MNCN), a rapidly growing, innovative, global wellness solutions company, announced it has completed the first tranche of its investment in PanTheryx, Inc., as stipulated in a recent Letter of Understanding signed in August 2009.Millipore Corporation (NYSE:MIL) a leading provider of technologies, tools and services for the global life science industry has been named “Corporate Citizen of the Year” by the New England Clean Energy Council.NeoGenomics, Inc. (OTC:NGNM) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City.Nutra Pharma Corp. (OTC:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever.Nile Therapeutics, Inc. (NASDAQ:NLTX), a company focused on the development of novel therapeutics for heart failure patients, announced its third quarter financial results for 2009.For the fiscal year ending June 30th, 2009, PD-Rx (Pink Sheets: PDRX) set record sales of $26.9 million over last year's sales figures of $26.4 million, reporting a net increase in sales of $493,230.PharmAthene, Inc. (NYSE:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported financial and operational results for the third quarter and nine months ended September 30, 2009.Repros Therapeutics Inc. (Nasdaq:RPRX) announced it has elected Dr. Jaye Thompson to its Board of Directors, and as a member of the Board’s Audit Committee, effective immediately.Shire plc (Nasdaq:SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®.In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.ULURU Inc. (NYSE:ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, announced it has entered into definitive agreements to sell 10,714,467 shares of its common stock at a price per share of $0.14 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $1.5 million.

Millipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks Consensus Estimate of 93 cents per share. Revenues for the third quarter grew 4% from the previous year, totaling $412 million. Excluding a 3% unfavorable impact from changes in foreign currency, Millipore generated organic revenue growth of 7%. On a divisional [...]

(MIL) Millipore Corporation Falls Short of Estimates

Millipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks Consensus Estimate of 93 cents per share.

Revenues for the third quarter grew 4% from the previous year, totaling $412 million. Excluding a 3% unfavorable impact from changes in foreign currency, Millipore generated organic revenue growth of 7%. On a divisional basis, excluding changes in foreign currency, Millipore’s Bioprocess Division generated organic revenue growth of  8%, while the company’s Bioscience Division generated organic revenue growth of 4% from the previous year. In the Americas, revenue grew by 4% year over year while Asia recorded a 16% growth in revenues when compared to a similar period.

Bioprocess Division is sustaining its strong momentum and generating very attractive growth. The division’s performance has returned to tracking the strong fundamentals of the biotech industry and there was also an additional benefit of an increase in vaccine productions.

The company continues to increase its R&D spending in the third quarter and it is improving its innovation capabilities. Higher growth and profitability gives it the opportunity to invest while the general market is in a downturn. This investment will benefit its competitive position over time. The company completed the acquisition of BioAnaLab to extend the Company’s biopharmaceutical services offering to the European market.

Cash and equivalents were $190 million with long-term debt at $907 million and shareowner’s equity was at $1.4 billion.

It generated approximately $112 million of free cash flow, representing 74 % growth over the third quarter of 2008.  It also paid down $57 million of borrowings under the company’s $678 million primary revolving credit facility, leaving approximately $14 million drawn against it at the end of the quarter.

Millipore is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, it collaborates with customers to confront the world's challenging human health issues. From research to development to production, its scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. The company was founded in 1954 and is headquartered in Billerica, Massachusetts. Major competitors of the company include Pall Corp. (PLL).

Read the full analyst report on "MIL"
Read the full analyst report on "PLL"
Zacks Investment Research